CA9 and cancer: Sulphonamide derivatives acting as effective CAIX inhibitors showed significant anticancer activity in vitro and/or in vivo in many cell types and cancer models, with one such compound, SLC-0111, presently in Phase Ib/II clinical trials for the management of advanced, metastatic solid tumours [18,21].